公司治理
业务
法令
基因工程
生物技术
消费者安全
产品(数学)
环境法规
政府监管
风险分析(工程)
转基因生物
合成生物学
消费者保护
环境规划
人类健康
公共经济学
立法
新产品开发
执行
生物
作者
Jennifer Kuzma,Christopher L. Cummings,Khara Grieger
标识
DOI:10.3389/fgene.2026.2008399
摘要
Living genetically engineered microorganisms (GEMs) are increasingly used in consumer products and environmental applications, yet U.S. biotechnology regulation relies on statutes that predate their development or are designed for other types of products. This article examines oversight of living GEMs through 3 case studies of consumer and environmental GEM applications. Across these cases, federal premarket review was very limited or absent because oversight depended on distinctions such as the type of modification, the developer's product classification, or marketing claims. These regulatory pathways may not always align uniformly with the potential health and environmental risk profiles. While not all GEMs require the same level of oversight, current regulatory gaps have allowed for the large-scale, open release of these GEMs without substantial federal oversight. The article recommends baseline federal notification, changes to statutes or regulations to strengthen regulatory foundations, greater transparency, independent evaluation, and post-market monitoring, while also preserving efficient pathways for lower-risk applications. These enhancements to the regulation of GEMs will become increasingly important for effective risk governance as consumer and environmental products incorporate advanced synthetic biology approaches.
科研通智能强力驱动
Strongly Powered by AbleSci AI